Results 71 to 80 of about 4,419,243 (284)
Outcomes of Temporary Percutaneous Right Ventricular Assist Devices in Right Ventricular Failure
Purpose Right ventricular failure occurs in a variety of clinical settings and is associated with worse survival. We describe our clinical experience with two temporary percutaneous right ventricular assist devices (RVADs): TandemLife Protek Duo (TPD) and Impella RP.
A. Akhmerov +8 more
openaire +1 more source
Innate Immunocompetent hiPSC‐Derived Neurospheroids Capture Early CNS Responses to rAAV
Knowledge of human CNS immune responses to AAV‐based gene therapies remains limited due to the lack of immune‐competent human models. Here, a hiPSC‐derived 3D neuroimmune platform integrating neurospheroids and microglia is established using stirred‐tank bioreactors.
Catarina M. Gomes +14 more
wiley +1 more source
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang +6 more
wiley +1 more source
The Mind From Within: Visceral Roots of Human Cognition
The physiological activity of visceral organs, such as the heart, the lungs, and the gut, is surprisingly linked to many sophisticated mental operations, such as remembering the past, being aware of ourselves, making choices, and forging social bonds.
Alessandro Monti +1 more
wiley +1 more source
The cost-effectiveness of left ventricular assist devices in end stage heart failure
With a limited supply of donor hearts, individuals with end-stage heart failure have been offered hope through the use of mechanical devices. Left ventricular-assist devices (LVADs) are a technology designed to work in parallel with the heart but have ...
Bryant, Jackie +6 more
core +1 more source
Successful use of a right ventricular assist device. [PDF]
Right ventricular failure caused by myocardial infarction may be refractory to treatment designed to support the systemic ventricle. A new type of right ventricular assist device driven by an impeller pump was successfully used for 79 hours after emergency revascularisation after right coronary occlusion. Despite renal failure requiring haemofiltration
P, Belcher, B, Glenville, L, Cooper
openaire +2 more sources
Molecular editing of bilobalide uncovers BB56, a PREP‐engaging chemotype with enhanced anti‐inflammatory activity in microglia. Integrated CETSA‐MS, SAR, and pathway analyses link BB56 to attenuation of p38 MAPK/NF‐κB and NLRP3‐associated inflammatory signaling, highlighting bilobalide editing as a strategy for developing neuroinflammation‐modulating ...
Chanin Sillapachaiyaporn +20 more
wiley +1 more source
Tunneling a Pulmonary Artery Graft: A Simplified Way to Insert and Remove a Temporary Right Ventricular Assist Device [PDF]
Right ventricular failure can occur early or late after left ventricular assist device implantation. Support with a right ventricular assist device is needed in patients whose right ventricular failure does not respond to conservative management. The use
Marasco, Silvana F, Saxena, Pankaj
core +1 more source
Background: Right ventricular failure (RVF) remains a major determinant of morbidity and mortality following left ventricular assist device (LVAD) implantation. In its most severe form, RVF necessitates right ventricular assist device (
Maria Comanici +11 more
doaj +1 more source
Aims Phosphodiesterase‐5 inhibitors (PDE5I) are frequently implemented after left ventricular assist device (LVAD) implantation to improve haemodynamics in patients with early postoperative right ventricular (RV) failure. It is unknown if long‐term PED5I
Maria Papathanasiou +6 more
doaj +1 more source

